Single ascending dosea | Multiple ascending dosea | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Demographics and disease characteristics | IV | SC | SC Q4W × 4 | ||||||||
Placebob | 1 mg | 3 mg | 10 mg | 30 mg | 10 mg | 30 mg | Placebo | 3 mg | 10 mg | 20 mg | |
(N = 12) | (N = 6) | (N = 6) | (N = 5) | (N = 6) | (N = 5) | (N = 6) | (N = 6) | (N = 6) | (N = 6) | (N = 6) | |
Age, years | 25.2 | 35.0 | 30.2 | 22.8 | 46.7 | 31.6 | 28.2 | 54.7 | 53.0 | 48.7 | 52.7 |
(6.3) | (12.0) | (11.2) | (2.8) | (5.0) | (9.2) | (9.5) | (9.7) | (6.8) | (8.7) | (5.5) | |
Weight, kg | 73.1 | 73.8 | 76.8 | 71.2 | 74.2 | 82.8 | 76.7 | 81.5 | 93.4 | 101 | 112 |
(91) | (6.5) | (7.8) | (12.2) | (10.0) | (8.9) | (10.7) | (6.1) | (18.1) | (16.5) | (10.3) | |
Male, % | 92 | 100 | 100 | 100 | 83 | 100 | 100 | 17 | 67 | 50 | 50 |
Mean total WOMAC score | nac | na | na | na | na | na | na | 51.1 | 46.3 | 49.8 | 68.7 |
(9.3) | (6.4) | (8.1) | (3.7) | ||||||||
Mean VAS score of patients’ disease assessments | na | na | na | na | na | na | na | 35.5 | 52.3 | 48.3 | 59.0 |
(8.3) | (8.0) | (6.6) | (6.0) | ||||||||
Mean score of physician’s disease assessments | na | na | na | na | na | Na | na | 2.17 | 2.33 | 2.50 | 2.00 |
(0.48) | (0.33) | (0.22) | (0.26) |